Trial
NCT00000856
A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
Encephalopathy
Intervention
Foscarnet sodium
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-29